Press releases

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD

Atriva Therapeutics Starts Clinical Development of Novel Host-Targeting Antiviral ATR-002 Against Influenza

LightOx appoints experienced Non-Executive Directors and closes investment round

Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme

Galapagos steekt ruim €300 miljoen in zoektocht naar nieuwe medicijnen

Aanval op het bestverkochte medicijn ter wereld

De lamme laten lopen, de blinde laten zien

Japans Itochu steekt €10 mln in Waals stamcellenbedrijf

Novartis maakt Rotterdams medicijn zes keer duurder

Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices

Atriva Therapeutics announces first closing of series A financing round

Voor Big Farma zijn zeperds als Dezima part of the deal

Miljardendeal van biotechbedrijf Dezima loopt uit op flop

Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease

Miljoenendeal van Nijmeegs biotechbedrijf met Deense Novo Nordisk

Gentherapie verdient moderne regels

Nederland loopt investeringen voor gentherapie mis

Xenikos announces data from phase I/II trial with T-Guard™ for treatment of steroid-resistant acute GVHD presented at ASH Annual Meeting

Dutch Company Xenikos Secures USD 30 Million in Series B Financing

APTAMER GROUP LTD SECURES $ 2.2 M SERIES A INVESTMENT